Source
CSO-Obecure Ltd, Paz Towers, 5 Shoham St, Ramat Gan, 52121, Israel. nirbarak@post.tau.ac.il
Abstract
BACKGROUND:
Betahistine is an orally administered, centrally acting histamine H(1) receptor agonist with partial H(3) antagonistic activity and no H(2)-binding effects. In the past betahistine was clinically studied mainly as a vasodilator for conditions such as cluster headaches, vascular dementia and Meniere's disease, for which it is still used. In recent years, histamine was found to be a key neurotransmitter in the regulation of feeding behavior.
OBJECTIVE:
To provide a review of the developmental history and current research interests of betahistine.
METHODS:
All reports of betahistine use in animals and humans were retrieved and reviewed.
RESULTS/CONCLUSION:
The unique pharmacologic properties of betahistine point to its potential future use as an antiobesity agent.